Different effects of pravastatin and cerivastatin on the media of the carotid arteries as assessed by integrated backscatter ultrasound

Circulation Journal

Volumn 68, Issue 8, 2004, Pages 784-790

  Ito, Yoko ^a   Kawasaki, Masanori ^a   Yokoyama, Haruko ^a   Okubo, Munenori ^a   Sano, Keiji ^a   Arai, Masazumi ^a   Nishigaki, Kazuhiko ^a   Uno, Yoshihiro ^a   Takemura, Genzou ^a   Minatoguchi, Shinya ^a   Fujiwara, Hisayoshi ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

Arteriosclerosis; Integrated backscatter; Statin; Ultrasound

Indexed keywords

CERIVASTATIN; PRAVASTATIN;

ADULT; AGED; ARTERIOSCLEROSIS; ARTERY COMPLIANCE; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; B SCAN; CARDIOVASCULAR RESPONSE; CAROTID ARTERY; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYPERLIPIDEMIA; IMAGE ANALYSIS; INTEGRATED BACKSCATTER ULTRASOUND; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOOTH MUSCLE FIBER;

AGED; BODY MASS INDEX; CAROTID ARTERIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; PRAVASTATIN; PYRIDINES; TUNICA MEDIA;

EID: 3843111010     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.784     Document Type: Article

References (23)

1. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001; 357: 577-581.
2. Cupini LM, Pasqualetti P, Diomedi M, Vernieri F, Silvestrini M, Rizzate B, et al. Carotid artery intima-media thickness and lacunar versus nonlacunar infarcts. Stroke 2002; 33: 689-694.
3. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intima-media thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 2001; 104: 2815-2819.
4. The Long-Term Investigation with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patient with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med 1998; 339: 1349-1357.
5. Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Belder R, Park JS, et al. Koupio Atherosclerosis Prevention Study (KAPS): A population-based primary preventive trial of the effect of LDL lowing on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-1764.
6. Takiuchi S, Akugi H, Honda K, Masuyama T, Hirata N, Ito H, et al. Quantitative ultrasonic tissue characterization can identify high-risk atherosclerotic alteration in human carotid arteries. Circulation 2000; 102: 766-770.
7. Waki H, Masuyama T, Mori H, Maeda T, Kitade K, Moriyasu K, et al. Ultrasonic tissue characterization of the atherosclerotic carotid artery. Histological correlates of carotid integrated backscatter. Circ J 2003; 67: 1013-1016.
8. Kawasaki M, Takatsu H, Noda T, Ito Y, Kunishima A, Arai M, et al. Non-invasive tissue characterization of human atherosclerotic lesions in carotid and femoral arteries by ultrasound integrated backscatter: Comparison between histology and integrated backscatter images before and after death, J Am Coll Cardiol 2001; 38: 486-492.
9. Hayashi K, Handa H, Nagasawa S, Okumura A, Moritake K. Stiffness and elastic behavior of human intracranial and extracranial arteries. J Biomech 1980; 13: 175-184.
10. van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman RS, et al. Association between arterial stiffness and atherosclerosis: The Rotterdam Study. Stroke 2001; 32: 454-460.
11. Mannami T, Konishi M, Baba S, Nishi N, Terao A. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cerdiovascular risk factors in the general population of a Japanese city. Stroke 1997; 28: 518-525.
12. Rossi M, Cupisti A, Perrone L, Santoro G. Carotid ultrasound backscatter analysis in hypertensive and in healthy subjects. Ultrasound Med Biol 2002; 28: 1123-1128.
13. Hadjiisky P, Peyri N, Grosgogeat Y. Tunica media changes in the spontaneously hypertensive rat (SHR). Atherosclerosis 1987; 65: 125-137.
14. Hatanaka T. Clinical pharmacokinetics of pravastatin: Mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000; 39: 397-412.
15. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000; 23(Suppl 2): B72-B78.
16. Axel DI, Riessen R, Runge H, Viebahn R, Karsch KR. Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures in comparison to other statins. J Cardiovasc Pharmacol 2000; 35: 619-629.
17. Ichihara K, Satoh K. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet 2002; 359: 2195-2198.
18. Kool M, Lustermans F, Kragten H, Struijker Boudier H, Hoeks A, Reneman R, et al. Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol 1995; 48: 217-223.
19. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2022-2060.
20. Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, et al. Pravastatin, Lipids and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 75: 455-459.
21. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford ID, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigations. N Engl J Med 1996; 335: 1001-1009.
22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastati in men with hypercholesterolemia: West of Scotland Coronary Prevantion Study Group. N Engl J Med 1995; 333: 1301-1307.
23. Siegel-Axel DI. Cerivastatin: A cellular and molecular drug for the future? Cell Mol Life Sci 2003; 60: 144-164.